How many clinical trials are tracked for SARS-CoV-2 infection?

106 trials are tracked, 34 with published results.

SARS-CoV-2 infection Research

SARS-CoV-2 infection: current evidence & treatments

SARS-CoV-2 infection interacts with host E3 ubiquitin ligases to modulate viral replication and immune evasion, including inhibition of interferon production ¹. The virus can also induce intestinal dysbiosis and modify immune signaling, with potential effects on neuropsychiatric and metabolic complications via the microbiota-gut-brain axis ¹¹. Mechanistically, SARS-CoV-2 relies on ACE2 receptors and TMPRSS2-mediated membrane fusion, hijacks the endoplasmic reticulum to induce stress responses, and can be detected as particles measuring 70-100 nm in infected cell supernatants [18, 24].

Post-acute sequelae of COVID-19 include significant thromboembolic risk ², a 41% increased risk of new-onset diabetes ¹³, and cardiovascular manifestations that require mechanism-informed, subgroup-based management ⁷. Omicron variants are associated with increased prevalence of multisystem long COVID and gastrointestinal symptoms ²⁵. In children, two doses of SARS-CoV-2 vaccine show a protective effect against multisystem inflammatory syndrome (MIS-C) ¹⁴. For acute treatment, casirivimab plus imdevimab reduced risk of hospitalization or death in outpatients ³, while convalescent plasma did not reduce mortality in moderate to severe disease ¹⁵. Interleukin-7 therapy improved lymphocyte counts but did not reduce mortality in sepsis or COVID-19 ⁸.

Safety and pharmacokinetic data show that nirmatrelvir/ritonavir in breast milk results in low infant exposure (1.8% of maternal dose for nirmatrelvir) ²¹, and intramuscular adintrevimab for prophylaxis had a 2.0% incidence of systemic treatment-emergent adverse events within 7 days ¹⁹. Clozapine use in severe mental disorders is linked to higher SARS-CoV-2 infection risk ²². Inactivated SARS-CoV-2 vaccines (CoronaVac and Covilo) in adults aged 60-80 years induced neutralizing antibody geometric mean titers up to 59.4 under certain dosing schedules ²³. High COVID-19 immunization coverage (93.2%) was achieved in Ghana ¹⁰, and a semantic FAIRness framework has been proposed to enhance COVID-19 data integration in the UAE ⁴.

SARS-CoV-2 modulates host E3 ubiquitin ligases to evade immune responses and promote replication ¹.

Post-COVID syndrome carries significant thromboembolic risk ² and a 41% increased risk of new-onset diabetes ¹³.

Two doses of SARS-CoV-2 vaccine protect against MIS-C in children ¹⁴.

Casirivimab plus imdevimab reduces hospitalization or death in outpatients ³, while convalescent plasma does not reduce mortality ¹⁵.

Nirmatrelvir/ritonavir in breast milk results in low infant exposure ²¹.